Alto Neuroscience watches as FY2025 EPS misses, cash supports 2026 readouts
Signal reports FY2025 EPS of -$2.19 vs -$0.64 est; $177M cash runway into 2028 with four data catalysts
Alto Neuroscience (ANRO) is under the market's microscope after a trading signal flagged a full-year 2025 earnings miss that underscores the company's clinical-stage profile, even as its cash position and upcoming data readouts underpin investor optimism. The signal reported FY2025 earnings per share of -$2.19 against estimates of -$0.64, a notable shortfall. Company filings and recent disclosures show trailing twelve-month EPS of approximately -$2.30 as of late 2025, while Q3 2025 results reported a non-GAAP loss per share of -$0.52, narrower than the consensus estimate of -$0.68 at the time. Quarterly updates are available through the company's Q3 2025 release, and analysts are tracking the pending release of FY2025 results (expected around March 2026) for a complete picture.
Beyond the headline earnings figure, Alto Neuroscience's balance sheet has strengthened. As of September 30, 2025, cash, cash equivalents, and restricted cash totaled about $138.3 million. Following a $49.9 million private placement in October 2025, the cash balance rose to approximately $184.2 million, and management has guided that the cash position should support planned operations into 2028. The signal cited an operational cash runway figure of roughly $177 million into 2028, which is consistent with the company's updated balance sheet guidance and provides a clear path through four anticipated clinical study readouts.
Clinical progress remains central to Alto's story. Key catalysts ahead include topline Phase 2 data for ALTO-101 in cognitive impairment in schizophrenia, expected in the first quarter of 2026, and topline Phase 2b data for ALTO-300 in major depressive disorder, anticipated around mid-2026. ALTO-100 for bipolar depression continues enrollment with topline data projected in the second half of 2026. Additionally, following a successful FDA meeting, ALTO-207 for treatment-resistant depression is on track to initiate a Phase 2b trial in the first half of 2026 and a Phase 3 trial by early 2027, according to company disclosures. The pipeline's breadth and the schedule of data readouts underpin why investors remain focused on the stock despite near-term volatility.
The stock's trajectory reflects a mix of caution and anticipation. Shares have gained roughly 48% from February lows, supported by analyst optimism ahead of the upcoming data catalysts. As of mid-March 2026, the analyst consensus leans bullish, with a majority of ratings at Buy and an average price target in the low-$30s, according to market data. That represents meaningful upside from the current price around $22.26, indicating that the market is pricing in a favorable risk-reward for the upcoming readouts. Institutional ownership is significant, reflecting confidence in the company's precision psychiatry approach and its differentiated pipeline.
For investors, the primary near-term focus is execution on those four clinical readouts. Success could transform Alto's trajectory, while setbacks would likely weigh on shares. The cash runway into 2028 reduces immediate financing pressure, allowing management to prioritize data delivery. The signal's watch designation highlights the balance between the FY2025 earnings disappointment and the stock's recovery tied to anticipated catalysts. As Q1 2026 data from ALTO-101 approaches, investors will be looking for early validation of Alto's biomarker-driven approach in psychiatry.